Ocular Mucoadhesive and Biodegradable Spanlastics Loaded Cationic Spongy Insert for Enhancing and Sustaining the Anti-inflammatory Effect of Prednisolone Na Phosphate; Preparation, I-optimal Optimization, and In-vivo Evaluation

Overview

Journal Int J Pharm X

Specialty Pharmacology

Date 2024 Nov 5

PMID 39498272

Authors

Mayada Said

Khaled M Ali

Munerah M Alfadhel

Obaid Afzal

Basmah Nasser Aldosari

Maha Alsunbul

Rawan Bafail

Randa Mohammed Zaki

Affiliations

Soon will be listed here.

Abstract

This study aimed to formulate and statistically optimize spanlastics loaded spongy insert (SPLs-SI) of prednisolone Na phosphate (PRED) to enhance and sustain its anti-inflammatory effect in a controlled manner. An I-optimal optimization was employed using Design-Expert® software. The formulation variables were sonication time, the Span 60: EA ratio and type of edge activator (Tween 80 or PVA) while Entrapment efficiency (EE%), Vesicles' size (VS) and Zeta potential (ZP) were set as the dependent responses. This resulted in an optimum spanlastics (SPLs) formulation with a desirability of 0.919. It had a Span60:Tween80 ratio of 6:1 with a sonication time of 9.5 min. It was evaluated in terms of its EE%, VS, ZP, release behavior in comparison to drug solution in addition to the effect of aging on its characteristics. It had EE% of 87.56, VS of 152.2 nm and ZP of -37.38 Mv. It showed sustained release behavior of PRED in comparison to drug solution with good stability for thirty days. TEM images of the optimized PRED SPLs formulation showed spherical non-aggregated nanovesicles. Then it was loaded into chitosan spongy insert and evaluated in terms of its visual appearance, pH and mucoadhesion properties. It showed good mucoadhesive properties and pH in the safe ocular region. The FTIR, DSC and XRD spectra showed that PRED was successfully entrapped inside the SPLs vesicles. It was then exposed to an in-vivo studies where it was capable of enhancing the anti-inflammatory effect of PRED in a sustained manner with once daily application compared to commercial PRED solution. The spongy insert has the potential to be a promising carrier for the ocular delivery of PRED.

References

El Zaafarany G, Awad G, Holayel S, Mortada N . Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm. 2010; 397(1-2):164-72. DOI: 10.1016/j.ijpharm.2010.06.034. View

Seyfoddin A, Shaw J, Al-Kassas R . Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 2010; 17(7):467-89. DOI: 10.3109/10717544.2010.483257. View

Liu Y, Wang Y, Yang J, Zhang H, Gan L . Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production. Int J Pharm. 2019; 565:133-142. DOI: 10.1016/j.ijpharm.2019.05.018. View

Suttorp-Schulten M, Rothova A . The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996; 80(9):844-8. PMC: 505625. DOI: 10.1136/bjo.80.9.844. View

Janagam D, Wu L, Lowe T . Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev. 2017; 122:31-64. PMC: 6057481. DOI: 10.1016/j.addr.2017.04.001. View

Katzer T, Chaves P, Bernardi A, Pohlmann A, Guterres S, Beck R . Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity. J Microencapsul. 2014; 31(6):519-28. DOI: 10.3109/02652048.2013.879930. View

Zaki R, Alfadhel M, Alshahrani S, Alsaqr A, Al-Kharashi L, Anwer M . Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity against H-1975 Cell Lines. Pharmaceuticals (Basel). 2022; 15(3). PMC: 8948618. DOI: 10.3390/ph15030348. View

Said M, Elsayed I, Aboelwafa A, Elshafeey A . A novel concept of overcoming the skin barrier using augmented liquid nanocrystals: Box-Behnken optimization, ex vivo and in vivo evaluation. Colloids Surf B Biointerfaces. 2018; 170:258-265. DOI: 10.1016/j.colsurfb.2018.06.025. View

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

10.

Alonso M, Sanchez A . The potential of chitosan in ocular drug delivery. J Pharm Pharmacol. 2004; 55(11):1451-63. DOI: 10.1211/0022357022476. View

11.

El-Helw A, Fahmy U . Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers. Int J Nanomedicine. 2015; 10:5797-804. PMC: 4577263. DOI: 10.2147/IJN.S91556. View

12.

Bucolo C, Drago F, Salomone S . Ocular drug delivery: a clue from nanotechnology. Front Pharmacol. 2012; 3:188. PMC: 3486627. DOI: 10.3389/fphar.2012.00188. View

13.

Ngan C, Basri M, Lye F, Fard Masoumi H, Tripathy M, Abedi Karjiban R . Comparison of process parameter optimization using different designs in nanoemulsion-based formulation for transdermal delivery of fullerene. Int J Nanomedicine. 2014; 9:4375-86. PMC: 4172124. DOI: 10.2147/IJN.S65689. View

14.

Ghaderi S, Ghanbarzadeh S, Mohammadhassani Z, Hamishehkar H . Formulation of gammaoryzanol-loaded nanoparticles for potential application in fortifying food products. Adv Pharm Bull. 2015; 4(Suppl 2):549-54. PMC: 4312404. DOI: 10.5681/apb.2014.081. View

15.

ElMeshad A, Mohsen A . Enhanced corneal permeation and antimycotic activity of itraconazole against Candida albicans via a novel nanosystem vesicle. Drug Deliv. 2014; 23(7):2115-2123. DOI: 10.3109/10717544.2014.942811. View

16.

Grassiri B, Zambito Y, Bernkop-Schnurch A . Strategies to prolong the residence time of drug delivery systems on ocular surface. Adv Colloid Interface Sci. 2021; 288:102342. DOI: 10.1016/j.cis.2020.102342. View

17.

Zaki R, DevanathaDesikan Seshadri V, Mutayran A, Elsawaf L, Hamad A, Almurshedi A . Wound Healing Efficacy of Rosuvastatin Transethosomal Gel, I Optimal Optimization, Histological and In Vivo Evaluation. Pharmaceutics. 2022; 14(11). PMC: 9692372. DOI: 10.3390/pharmaceutics14112521. View

18.

Teabagy S, Wood E, Bilsbury E, Doherty S, Janardhana P, Lee D . Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis. Adv Drug Deliv Rev. 2023; 198:114869. PMC: 10330522. DOI: 10.1016/j.addr.2023.114869. View

19.

Conrady C, Yeh S . A Review of Ocular Drug Delivery Platforms and Drugs for Infectious and Noninfectious Uveitis: The Past, Present, and Future. Pharmaceutics. 2021; 13(8). PMC: 8399730. DOI: 10.3390/pharmaceutics13081224. View

20.

Ibrahim M, Abd-Elgawad A, Soliman O, Jablonski M . Stability and Ocular Pharmacokinetics of Celecoxib-Loaded Nanoparticles Topical Ophthalmic Formulations. J Pharm Sci. 2016; 105(12):3691-3701. DOI: 10.1016/j.xphs.2016.09.019. View